Capricor Therapeutics Reports Q2 Loss

- Company Misses Revenue Estimates

- Earnings and Revenue Surprises of -769 and -146 Respectively

Capricor Therapeutics (NASDAQ: CAPR) reported a quarterly loss of $0.35 per share, missing the Zacks Consensus Estimate of a loss of $0.11. The Company reported a net loss of approximately $110 million or $0.35 per share for the second quarter.

Capricor CAPR delivered earnings and revenue surprises of -769 and -146 respectively for the quarter ended June 2018.

Find the latest Capricor Therapeutics Inc CAPR stock quote, history, news and other vital information to help you with your investment decision making.